Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Construction in Progress (2021 - 2023)

Historic Construction in Progress for Arrowhead Pharmaceuticals (ARWR) over the last 3 years, with Q3 2023 value amounting to $166.7 million.

  • Arrowhead Pharmaceuticals' Construction in Progress rose 19562.91% to $166.7 million in Q3 2023 from the same period last year, while for Sep 2023 it was $166.7 million, marking a year-over-year increase of 19562.91%. This contributed to the annual value of $166.7 million for FY2023, which is 19562.91% up from last year.
  • Arrowhead Pharmaceuticals' Construction in Progress amounted to $166.7 million in Q3 2023, which was up 19562.91% from $118.3 million recorded in Q2 2023.
  • Arrowhead Pharmaceuticals' 5-year Construction in Progress high stood at $166.7 million for Q3 2023, and its period low was $345000.0 during Q3 2021.
  • Over the past 3 years, Arrowhead Pharmaceuticals' median Construction in Progress value was $56.4 million (recorded in 2022), while the average stood at $65.6 million.
  • Its Construction in Progress has fluctuated over the past 5 years, first skyrocketed by 1624000.0% in 2022, then surged by 19562.91% in 2023.
  • Quarter analysis of 3 years shows Arrowhead Pharmaceuticals' Construction in Progress stood at $2.2 million in 2021, then skyrocketed by 4092.15% to $90.2 million in 2022, then surged by 84.73% to $166.7 million in 2023.
  • Its last three reported values are $166.7 million in Q3 2023, $118.3 million for Q2 2023, and $127.2 million during Q1 2023.